The open-label trial compared orforglipron, an oral non-peptide GLP-1 receptor agonist, with titrated insulin glargine in 2749 adults with type 2 diabetes at increased cardiovascular risk, of whom 86% had established cardiovascular disease and 38% chronic kidney disease. The primary outcome was time to cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina, with non-inferiority declared if the upper limit of the 95% confidence interval for the hazard ratio was below 1.8.
Why it is interesting: Cardiovascular safety of a non-peptide GLP-1 receptor agonist set against an active comparator, with a stated non-inferiority margin of 1.8 on the hazard ratio.